Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Roche buy-in is another vote of confidence in gene therapy
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
Uniqure turns the screw on Spark and Pfizer
In the race to develop a haemophilia B gene therapy Uniqure now has the upper hand.
Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Tiny populations up the ante for gene therapy pricing
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
Ash 2018 preview – Freeline ziplines into haemophilia gene therapy
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
Haemophilia B race heats up with Uniqure data
Padua gambit seems to have worked as new gene therapy looks the equal of Pfizer/Spark Therapeutics.
How many million-dollar drugs can health systems tolerate?
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.